SecBot SecBot
SECBOTREPLAY Home › Report › APGE

APGE · Apogee Therapeutics entered into a revenue participation agreement with…

Apogee Therapeutics, Inc. · 8-K filed May 27, 2026 at 06:40 ET

At the news

BULLISHIMPACT 7/10

8-K filed May 27, 2026 at 06:40 ET

Apogee Therapeutics entered into a revenue participation agreement with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, including an upfront $100 million and up to $800 million in synthetic royalty funding for zumilokibart, plus access to $500 million in senior debt. The company also withdrew its cash runway guidance, signaling confidence in its financial position. Combined with its existing $1.3 billion cash, this positions Apogee to fund Phase 3 development and potential commercialization without equity dilution.

  • Upfront payment of $100 million from Blackstone Life Sciences for revenue share on zumilokibart sales.
  • Up to $800 million total synthetic royalty funding: $100M at signing, $100M upon Phase 3 enrollment, $200M upon positive Phase 3 data, and up to $400M upon FDA approval.
  • Up to $500 million in senior corporate debt available at mutual consent.
  • Apogee has $1.3 billion in current total cash, combined with the new capital to achieve self-sustainable profile without future equity financing.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access